MY183449A - Formulations of quinones for the treatment of ophthalmic diseases - Google Patents
Formulations of quinones for the treatment of ophthalmic diseasesInfo
- Publication number
- MY183449A MY183449A MYPI2012004738A MYPI2012004738A MY183449A MY 183449 A MY183449 A MY 183449A MY PI2012004738 A MYPI2012004738 A MY PI2012004738A MY PI2012004738 A MYPI2012004738 A MY PI2012004738A MY 183449 A MY183449 A MY 183449A
- Authority
- MY
- Malaysia
- Prior art keywords
- quinones
- formulation
- treatment
- formula
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000004053 quinones Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000014674 injury Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000008733 trauma Effects 0.000 abstract 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32854610P | 2010-04-27 | 2010-04-27 | |
| US39369310P | 2010-10-15 | 2010-10-15 | |
| PCT/US2011/033983 WO2011137126A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY183449A true MY183449A (en) | 2021-02-18 |
Family
ID=44861894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012004738A MY183449A (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130109759A1 (https=) |
| EP (1) | EP2563352A4 (https=) |
| JP (2) | JP5902673B2 (https=) |
| CN (2) | CN105147651A (https=) |
| AU (1) | AU2011245384C1 (https=) |
| BR (1) | BR112012027543A8 (https=) |
| CA (1) | CA2797581A1 (https=) |
| EA (1) | EA201201465A1 (https=) |
| MX (1) | MX337594B (https=) |
| MY (1) | MY183449A (https=) |
| SG (2) | SG10201801321XA (https=) |
| WO (1) | WO2011137126A1 (https=) |
| ZA (1) | ZA201208535B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| ES2619303T3 (es) * | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| WO2007100652A2 (en) | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EA038941B1 (ru) | 2007-11-06 | 2021-11-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |
| US8952071B2 (en) * | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| JP5798481B2 (ja) * | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| CA2777479C (en) | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| NO2470168T3 (https=) * | 2009-08-26 | 2018-06-30 | ||
| CA2795726A1 (en) * | 2010-04-06 | 2011-10-13 | Edison Pharmaceuticals, Inc. | Treatment of ataxia telangiectasia |
| JP5902673B2 (ja) * | 2010-04-27 | 2016-04-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼疾患の処置のためのキノンの製剤 |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Ptc Therapeutics, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| DK3233786T3 (da) | 2014-12-16 | 2022-05-09 | Ptc Therapeutics Inc | Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid |
| WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2019070917A1 (en) * | 2017-10-03 | 2019-04-11 | The Schepens Eye Research Institute, Inc. | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME |
| TN2021000075A1 (en) | 2018-10-17 | 2023-01-05 | Ptc Therapeutics Inc | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS |
| KR20220012940A (ko) * | 2019-05-28 | 2022-02-04 | 엘간 파마 리미티드 | 망막병증 치료용 조성물 및 방법 |
| MX2024000445A (es) | 2021-07-08 | 2024-04-05 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilc iclohexa-2,5-dieno-1,4-diona. |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619303T3 (es) * | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| CA2850858A1 (en) * | 2005-09-16 | 2007-04-05 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| WO2007100652A2 (en) * | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| MX363223B (es) * | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| NO2470168T3 (https=) * | 2009-08-26 | 2018-06-30 | ||
| CA2795726A1 (en) * | 2010-04-06 | 2011-10-13 | Edison Pharmaceuticals, Inc. | Treatment of ataxia telangiectasia |
| JP5902673B2 (ja) * | 2010-04-27 | 2016-04-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼疾患の処置のためのキノンの製剤 |
-
2011
- 2011-04-26 JP JP2013508167A patent/JP5902673B2/ja not_active Expired - Fee Related
- 2011-04-26 CN CN201510490746.XA patent/CN105147651A/zh active Pending
- 2011-04-26 BR BR112012027543A patent/BR112012027543A8/pt not_active IP Right Cessation
- 2011-04-26 AU AU2011245384A patent/AU2011245384C1/en not_active Ceased
- 2011-04-26 MX MX2012012518A patent/MX337594B/es active IP Right Grant
- 2011-04-26 CA CA2797581A patent/CA2797581A1/en not_active Abandoned
- 2011-04-26 CN CN2011800317444A patent/CN102985083A/zh active Pending
- 2011-04-26 US US13/643,542 patent/US20130109759A1/en not_active Abandoned
- 2011-04-26 WO PCT/US2011/033983 patent/WO2011137126A1/en not_active Ceased
- 2011-04-26 MY MYPI2012004738A patent/MY183449A/en unknown
- 2011-04-26 EA EA201201465A patent/EA201201465A1/ru unknown
- 2011-04-26 SG SG10201801321XA patent/SG10201801321XA/en unknown
- 2011-04-26 SG SG2012079323A patent/SG185046A1/en unknown
- 2011-04-26 EP EP11775506.6A patent/EP2563352A4/en not_active Withdrawn
-
2012
- 2012-11-13 ZA ZA2012/08535A patent/ZA201208535B/en unknown
-
2016
- 2016-03-10 JP JP2016046881A patent/JP6266674B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,831 patent/US20170354618A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201208535B (en) | 2016-06-29 |
| AU2011245384A1 (en) | 2012-12-06 |
| AU2011245384C1 (en) | 2016-09-01 |
| SG185046A1 (en) | 2012-12-28 |
| AU2011245384B2 (en) | 2016-02-18 |
| JP2016106144A (ja) | 2016-06-16 |
| EP2563352A1 (en) | 2013-03-06 |
| JP2013525443A (ja) | 2013-06-20 |
| CN102985083A (zh) | 2013-03-20 |
| EP2563352A4 (en) | 2013-11-13 |
| JP5902673B2 (ja) | 2016-04-13 |
| WO2011137126A1 (en) | 2011-11-03 |
| US20170354618A1 (en) | 2017-12-14 |
| CN105147651A (zh) | 2015-12-16 |
| EA201201465A1 (ru) | 2013-04-30 |
| MX337594B (es) | 2016-03-11 |
| JP6266674B2 (ja) | 2018-01-24 |
| US20130109759A1 (en) | 2013-05-02 |
| SG10201801321XA (en) | 2018-04-27 |
| CA2797581A1 (en) | 2011-11-03 |
| MX2012012518A (es) | 2012-12-17 |
| BR112012027543A8 (pt) | 2019-12-03 |
| BR112012027543A2 (pt) | 2019-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY183449A (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| MX2011011310A (es) | Formulacion de tocotrienol quinonas para el tratamiento de enfermedades oftalmicas. | |
| WO2014096425A3 (en) | Prodrugs of monomethyl fumarate (mmf) | |
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| CA2711696C (en) | Therapeutic compositions for treatment of ocular inflammatory disorders | |
| WO2012009171A3 (en) | Compositions and methods of treatment of corneal endothelium disorders | |
| HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
| HK1213888A1 (zh) | 治療化合物和組合物以及其作為pkm2調節劑的用途 | |
| WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| MX2014011946A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| AU2013218357A8 (en) | Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors | |
| TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| MX2013002121A (es) | Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| WO2014070696A3 (en) | Treatment of chronic dermal inflammatory with norketotifen | |
| AU2014352875A8 (en) | Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis | |
| WO2017129577A8 (en) | Ophthalmic gabapentin for the treatment of corneal ulcers | |
| AU2014216273A8 (en) | Topical ocular analgesic agents | |
| WO2013049272A3 (en) | Composition and method for treatment of symptoms associated with various skin conditions | |
| MX2013002295A (es) | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| HK1210173A1 (en) | Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators |